TAIM

VistaJet launches aviation's first 360 Wellness program at altitude and at destination

Retrieved on: 
Mardi, octobre 24, 2023
Knowledge, Geoffrey Kent, Relaxation, Light fixture, Health, TAIM, Heart, Life, Posture, Atti, Skin, Atmosphere, Coffee, Private, Athlete, Taj Hotels, Immersion, Nature, Botswana Private Medical & Health Services Workers' Union, Ice, Learning, Our Private World, Silver, Medicine, Traditional Arabic, Bombardier Global 7500, Privacy, WELL, Genolier, Meditation, Nutritionist, McKinsey & Company, Collection, Wellness, Sami, VistaJet, Longevity, Tourism, Airline, Medical device, Hotel, Yoga, Buddhism

Continuing to challenge the boundaries of what is possible at 40,000 feet, VistaJet’s latest initiative is no less impressive — introducing the VistaJet Wellness program .

Key Points: 
  • Continuing to challenge the boundaries of what is possible at 40,000 feet, VistaJet’s latest initiative is no less impressive — introducing the VistaJet Wellness program .
  • Wellness at destination: from biohacking treatments to a private prayer session with the Tibetan Buddhist leader.
  • VistaJet has been on a journey to transform time spent in the air — to make it something to savor.
  • From Private Dining and now Wellness, VistaJet continues to pioneer a better way to fly — and live.

TargImmune Announces Successful Completion of GLP/Tox Studies and Further Reinforcement of Leadership Team with Hire of Head of Technical Development

Retrieved on: 
Mardi, juin 7, 2022
Head, EGFR, Survival, Cell death, TAIM, CEO, RNA, Degenerative disease, Cancer, Therapy, IND, Patient, Technology, CTA, Change request, History, Taim Hasan, CMC, Apoptosis, Vaccine, Medical imaging

Dr Thommen adds to an impressive senior management team at TargImmune, bringing more than 20 years of experience in biopharmaceutical drug development and scaling biotech manufacturing to clinical supply and commercial launch.

Key Points: 
  • Dr Thommen adds to an impressive senior management team at TargImmune, bringing more than 20 years of experience in biopharmaceutical drug development and scaling biotech manufacturing to clinical supply and commercial launch.
  • Marc's strong history of building CMC organisations at this point in their development will give us the expertise we need to continue to progress the development of our Ta:RNA platform towards patients."
  • I look forward to playing my part in the production of what promises to be an exciting new approach to cancer therapy."
  • TargImmune is dedicated to significantly improving the survival of cancer patients by developing novel targeted anti-cancer therapies which provide a multi-pronged attack against solid tumours.

TargImmune Announces Successful Completion of GLP/Tox Studies and Further Reinforcement of Leadership Team with Hire of Head of Technical Development

Retrieved on: 
Mardi, juin 7, 2022
Head, EGFR, Survival, Cell death, TAIM, CEO, RNA, Degenerative disease, Cancer, Therapy, Multimedia, IND, Patient, Technology, CTA, Change request, History, Taim Hasan, CMC, Apoptosis, Vaccine, Medical imaging

Dr Thommen adds to an impressive senior management team at TargImmune, bringing more than 20 years of experience in biopharmaceutical drug development and scaling biotech manufacturing to clinical supply and commercial launch.

Key Points: 
  • Dr Thommen adds to an impressive senior management team at TargImmune, bringing more than 20 years of experience in biopharmaceutical drug development and scaling biotech manufacturing to clinical supply and commercial launch.
  • Marc's strong history of building CMC organisations at this point in their development will give us the expertise we need to continue to progress the development of our Ta:RNA platform towards patients."
  • I look forward to playing my part in the production of what promises to be an exciting new approach to cancer therapy."
  • TargImmune is dedicated to significantly improving the survival of cancer patients by developing novel targeted anti-cancer therapies which provide a multi-pronged attack against solid tumours.

TargImmune Announces Another Senior Hire as Veronica Hersberger Revealed As New Chief Medical Officer

Retrieved on: 
Lundi, février 7, 2022
CFO, Apoptosis, EGFR, RNA, Trastuzumab emtansine, CTA, Hoffmann-La Roche, Multimedia, New Drug Application, Immune system, Cancer, Therapy, Pharmaceutical industry, IND, CMO, Technology, Patient, Cell death, Survival, Trastuzumab/hyaluronidase, CEO, Degenerative disease, Taim Hasan, AstraZeneca, TAIM, Haemophilia, Stomach, Management, Medical imaging, Medical device, Vaccine

Dr Hersberger joins TargImmune from AstraZeneca, where she was Global Product Leader for the cancer therapies Calquence and Lumoxiti.

Key Points: 
  • Dr Hersberger joins TargImmune from AstraZeneca, where she was Global Product Leader for the cancer therapies Calquence and Lumoxiti.
  • Speaking about her appointment, Dr Hersberger said, "I am very much looking forward to joining the TargImmune team at this important time.
  • "Dr Hersberger's decision to join the TargImmune team reflects the potential of our first-in-class Ta:RNA platform," said Peter Braun, TargImmune CEO.
  • TargImmune Therapeutics AG Peter Braun, CEO [email protected]
    TargImmune Therapeutics AG is a privately owned Swiss-based biotechnology company based in Basel and founded in 2016.

TargImmune Announces Another Senior Hire as Veronica Hersberger Revealed As New Chief Medical Officer

Retrieved on: 
Lundi, février 7, 2022
CFO, Apoptosis, EGFR, RNA, Trastuzumab emtansine, CTA, Hoffmann-La Roche, New Drug Application, Immune system, Cancer, Therapy, Pharmaceutical industry, IND, CMO, Technology, Patient, Cell death, Survival, Trastuzumab/hyaluronidase, CEO, Degenerative disease, Taim Hasan, AstraZeneca, TAIM, Haemophilia, Stomach, Management, Medical imaging, Medical device, Vaccine

Dr Hersberger joins TargImmune from AstraZeneca, where she was Global Product Leader for the cancer therapies Calquence and Lumoxiti.

Key Points: 
  • Dr Hersberger joins TargImmune from AstraZeneca, where she was Global Product Leader for the cancer therapies Calquence and Lumoxiti.
  • Speaking about her appointment, Dr Hersberger said, "I am very much looking forward to joining the TargImmune team at this important time.
  • "Dr Hersberger's decision to join the TargImmune team reflects the potential of our first-in-class Ta:RNA platform," said Peter Braun, TargImmune CEO.
  • TargImmune Therapeutics AG Peter Braun, CEO [email protected]
    TargImmune Therapeutics AG is a privately owned Swiss-based biotechnology company based in Basel and founded in 2016.